NASDAQ:QTNT - Quotient Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.25
  • Forecasted Upside: 837.50 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.24
+0 (0.00%)

This chart shows the closing price for QTNT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Quotient Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QTNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QTNT

Analyst Price Target is $2.25
▲ +837.50% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Quotient in the last 3 months. The average price target is $2.25, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 837.50% upside from the last price of $0.24.

This chart shows the closing price for QTNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Quotient. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/29/2022CowenLower Price TargetOutperform$9.00 ➝ $3.00Low
6/29/2022CowenLower Price TargetOutperform$9.00 ➝ $3.00Low
6/29/2022BTIG ResearchLower Price TargetBuy$9.00 ➝ $1.50Low
4/19/2022The Goldman Sachs GroupLower Price TargetNeutral$3.00 ➝ $1.50Medium
12/3/2021The Goldman Sachs GroupLower Price TargetNeutral$4.00 ➝ $3.50Medium
8/6/2021The Goldman Sachs GroupLower Price TargetNeutral$5.00 ➝ $4.50High
6/3/2021The Goldman Sachs GroupInitiated CoverageNeutral$5.00Medium
8/19/2020Jefferies Financial GroupReiterated RatingBuy$13.50Low
3/5/2019Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.50High
5/30/2018BTIG ResearchReiterated RatingBuy$10.00Low
5/20/2018BTIG ResearchSet Price TargetBuy$10.00Medium
3/27/2018BTIG ResearchReiterated RatingBuy$10.00Low
11/1/2017BTIG ResearchReiterated RatingBuy$12.00N/A
11/1/2017Jefferies Financial GroupLower Price TargetBuy$15.00 ➝ $13.00N/A
8/31/2017BTIG ResearchReiterated RatingBuy ➝ Buy$12.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 12 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
12/7/2021
  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/6/2022
  • 7 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
2/5/2022
  • 2 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
3/7/2022
  • 7 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/6/2022
  • 3 very positive mentions
  • 13 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/6/2022
  • 3 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/5/2022
  • 4 very positive mentions
  • 17 positive mentions
  • 12 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 4 very positive mentions
  • 17 positive mentions
  • 12 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Quotient logo
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ COVID-19 Microarray that is designed as a serological disease screening microarray specific to COVID-19 antibody detection. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Read More

Today's Range

Now: $0.24
Low: $0.24
High: $0.24

50 Day Range

MA: $0.40
Low: $0.24
High: $0.66

52 Week Range

Now: $0.24
Low: $0.23
High: $3.82

Volume

33,451 shs

Average Volume

1,019,364 shs

Market Capitalization

$24.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Quotient?

The following sell-side analysts have issued stock ratings on Quotient in the last twelve months: BTIG Research, Cowen Inc, Cowen Inc., StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for QTNT.

What is the current price target for Quotient?

0 Wall Street analysts have set twelve-month price targets for Quotient in the last year. Their average twelve-month price target is $2.25, suggesting a possible upside of 837.5%.
View the latest price targets for QTNT.

What is the current consensus analyst rating for Quotient?

Quotient currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe QTNT will outperform the market and that investors should add to their positions of Quotient.
View the latest ratings for QTNT.

How do I contact Quotient's investor relations team?

Quotient's physical mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company's listed phone number is (122) 716-9800 and its investor relations email address is [email protected] The official website for Quotient is www.quotientbd.com. Learn More about contacing Quotient investor relations.